Olaplex makes first acquisition with biotech bet – is this beauty’s next science race?

From the beginning, Olaplex has thrived on breaking the mould. A decade ago, it changed the conversation in haircare with bond-building technology that felt closer to a lab discovery than a salon launch. Now, ten years on, the company has taken another big step,  announcing its first-ever acquisition of Boston-based biotech company Purvala Bioscience.

At first glance, this might seem like just another beauty M&A deal. But in reality, it says something bigger about where the industry is headed.

Founded in 2020 by a team of MIT-linked scientists, including Professor of Chemical Engineering Dr. Bradley Olsen, Purvala has been developing high-performing molecules inspired by natural biological structures. It’s biotech for creating practical applications across health and beauty.

For Olaplex, this is more than a add-on, it’s a way of reminding us of its original ethos od disruptive innovation.

"Since the very beginning, Olaplex was founded on the concept of innovation with groundbreaking bond technology," said CEO Amanda Baldwin. "With Purvala we have the potential to create the next generation of disruptive science-backed product innovation alongside our patent-protected bond-building technology, Bis-amino."

The timing is interesting. Prestige haircare is more competitive than ever, with rivals launching their own versions of bond-repair treatments. At the same time, biotech is rapidly becoming beauty’s hottest asset, just look at Estée Lauder’s biotech investments and L’Oréal’s moves in biomaterials.

For Olaplex, acquiring Purvala could be both a defensive and an offensive play: protecting its market position while laying the groundwork for new categories of innovation. It also signals something important about consumer demand. The appetite for "science-backed beauty" is no longer confined to skincare serums boasting dermatological testing. In haircare, too, shoppers are seeking proof, patents and performance.

But, translating early-stage biotech research into consumer-ready formulations is no easy feat, and the industry has seen plenty of hype around scientific acquisitions that took years to bear fruit. But Olaplex’s decision to bet on Purvala suggests a long-term vision: a belief that the next wave of growth won’t just come from clever marketing or trend-driven NPD, but from science that sets new standards.

Olaplex is once again signalling that it intends not just to participate in beauty’s future, but to shape it.